These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36210625)

  • 21. Enhanced production of CTGF and IL-11 from highly metastatic hepatoma cells under hypoxic conditions: an implication of hepatocellular carcinoma metastasis to bone.
    Gao YB; Xiang ZL; Zhou LY; Wu ZF; Fan J; Zeng HY; Zeng ZC
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):669-79. PubMed ID: 23307318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
    Sakurai T; Yada N; Hagiwara S; Arizumi T; Minaga K; Kamata K; Takenaka M; Minami Y; Watanabe T; Nishida N; Kudo M
    Cancer Sci; 2017 Oct; 108(10):1996-2003. PubMed ID: 28777492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/β-catenin pathway.
    Lin Y; Jian Z; Jin H; Wei X; Zou X; Guan R; Huang J
    Cell Death Dis; 2020 Jan; 11(1):34. PubMed ID: 31949128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.
    Ding H; Zhang X; Su Y; Jia C; Dai C
    Cell Mol Biol Lett; 2020; 25():8. PubMed ID: 32123532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines.
    Huber A; Allam AH; Dijkstra C; Thiem S; Huynh J; Poh AR; Konecnik J; Jacob SP; Busuttil R; Liao Y; Chisanga D; Shi W; Alorro MG; Forrow S; Tauriello DVF; Batlle E; Boussioutas A; Williams DS; Buchert M; Ernst M; Eissmann MF
    Cell Rep; 2024 Aug; 43(8):114616. PubMed ID: 39128004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation.
    Mills LD; Zhang Y; Marler RJ; Herreros-Villanueva M; Zhang L; Almada LL; Couch F; Wetmore C; Pasca di Magliano M; Fernandez-Zapico ME
    J Biol Chem; 2013 Apr; 288(17):11786-94. PubMed ID: 23482563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
    Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
    Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells.
    Nagathihalli NS; Castellanos JA; VanSaun MN; Dai X; Ambrose M; Guo Q; Xiong Y; Merchant NB
    Oncotarget; 2016 Oct; 7(40):65982-65992. PubMed ID: 27602757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice.
    Schumacher N; Yan K; Gandraß M; Müller M; Krisp C; Häsler R; Carambia A; Nofer JR; Bernardes JP; Khouja M; Thomsen I; Chalupsky K; Bolik J; Hölscher C; Wunderlich T; Herkel J; Rosenstiel P; Schramm C; Schlüter H; Renné T; Mittrücker HW; Rose-John S; Schmidt-Arras D
    J Hepatol; 2021 Feb; 74(2):407-418. PubMed ID: 32987028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STAT3 activation in monocytes accelerates liver cancer progression.
    Wu WY; Li J; Wu ZS; Zhang CL; Meng XL
    BMC Cancer; 2011 Dec; 11():506. PubMed ID: 22136659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration.
    Lam SP; Luk JM; Man K; Ng KT; Cheung CK; Rose-John S; Lo CM
    Liver Transpl; 2010 Oct; 16(10):1195-206. PubMed ID: 20879018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mouse models for human colorectal cancer with liver metastasis].
    Huang XD; Zheng YB; Yang YJ; Yang C; Li HL; Cheng HR
    Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(34):2701-2705. PubMed ID: 31505723
    [No Abstract]   [Full Text] [Related]  

  • 35. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.
    Grabner B; Schramek D; Mueller KM; Moll HP; Svinka J; Hoffmann T; Bauer E; Blaas L; Hruschka N; Zboray K; Stiedl P; Nivarthi H; Bogner E; Gruber W; Mohr T; Zwick RH; Kenner L; Poli V; Aberger F; Stoiber D; Egger G; Esterbauer H; Zuber J; Moriggl R; Eferl R; Győrffy B; Penninger JM; Popper H; Casanova E
    Nat Commun; 2015 Mar; 6():6285. PubMed ID: 25734337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Connective tissue growth factor reacts as an IL-6/STAT3-regulated hepatic negative acute phase protein.
    Gressner OA; Peredniene I; Gressner AM
    World J Gastroenterol; 2011 Jan; 17(2):151-63. PubMed ID: 21245987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
    Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
    Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model.
    Hatting M; Spannbauer M; Peng J; Al Masaoudi M; Sellge G; Nevzorova YA; Gassler N; Liedtke C; Cubero FJ; Trautwein C
    Cell Death Dis; 2015 Mar; 6(3):e1667. PubMed ID: 25741592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.
    Xiang DM; Sun W; Ning BF; Zhou TF; Li XF; Zhong W; Cheng Z; Xia MY; Wang X; Deng X; Wang W; Li HY; Cui XL; Li SC; Wu B; Xie WF; Wang HY; Ding J
    Gut; 2018 Sep; 67(9):1704-1715. PubMed ID: 28754776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.